Hematology Month in Review: July 2024

July’s hematology month in review underlines the field’s forward stride in improving care, with key updates to the hematological pipeline and study data on benefiting patient outcomes. Recent trials have demonstrated notable advances in treatments for hematological conditions. AFFINE showed giroctocogene fitelparvovec significantly reduces bleeding rates in hemophilia A patients compared with standard prophylaxis, while XTEND-Kids confirmed the benefit of once weekly efanesoctocog alfa for children with the condition. REACH5 showed ruxolitinib's effectiveness and tolerability in pediatric chronic graft-versus-host disease